NDAINTRAVENOUSSOLUTION
Approved
Feb 2012
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
5
Data completeness
4/8 — Partial
SODIUM NITRITE (sodium nitrite) by Hope Pharmaceuticals. Approved for subarachnoid hemorrhage, acute myocardial infarction, acute respiratory distress syndrome and 5 more indications. First approved in 2012.
Drug data last refreshed 19h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Sodium nitrite is an intravenous solution approved in 2012 for multiple acute and chronic indications including subarachnoid hemorrhage, acute myocardial infarction, acute respiratory distress syndrome, sickle cell disease, and COVID-19. The drug functions as a vasodilator and nitric oxide donor, though its precise mechanism of action varies by indication. It is currently in peak lifecycle stage under Hope Pharmaceuticals sponsorship.
Peak5.6 years to LOE
Peak lifecycle status suggests stable commercial operations, though lack of published spending data indicates a niche acute-care positioning with focused commercial infrastructure.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Worked on SODIUM NITRITE at Hope Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.